Frataxin messenger RNA (FXN mRNA)

Frataxin messenger RNA (FXN mRNA) is the transcript of the FXN gene, which encodes the essential mitochondrial protein frataxin (NIH, 2023). Frataxin plays a pivotal role in cellular iron metabolism, specifically serving as a chaperone for the assembly of iron-sulfur (Fe-S) clusters required for the mitochondrial respiratory chain and various metabolic enzymes (PubMed, 2018). In Friedreich's ataxia (FRDA), a GAA trinucleotide repeat expansion in the first intron of the FXN gene leads to epigenetic silencing and a profound reduction in FXN mRNA levels (NeurologyLive, 2023). This deficiency results in mitochondrial dysfunction, iron accumulation, and increased sensitivity to oxidative stress, leading to progressive neurodegeneration and cardiomyopathy (Ataxia.org.uk, 2024). Therapeutic interventions targeting FXN mRNA aim to restore frataxin protein levels through several modalities, including mRNA replacement therapy, antisense oligonucleotides (ASOs) for transcript stabilization or splicing correction, and small molecules like GeneTACs that unblock transcription (CureFA.org, 2022). For instance, DT-216 is a clinical-stage molecule designed to specifically target the GAA expansion to restore endogenous mRNA production (Design Therapeutics, 2023). Monitoring FXN mRNA and protein levels in tissues like skeletal muscle or peripheral blood serves as a critical biomarker for evaluating the efficacy of these emerging treatments (Friedreich's Ataxia News, 2022).

Other names

FXN transcriptFrataxin mRNAFXN messenger RNA

Mechanisms of action for drugs targeting FXN mRNA include mRNA replacement therapy (delivery of synthetic transcripts), transcriptional unblocking (GeneTAC molecules that bypass GAA repeat-mediated silencing), and antisense oligonucleotide (ASO) strategies for transcript stabilization or splicing modulation.